Efficacy and Safety of Trastuzumab Deruxtecan in Heavily Pretreated Predominantly Low HER2 Expressing Gynecologic Malignancies

Background/Objectives: DESTINY-PanTumor02 demonstrated clinically meaningful activity of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing solid tumors, including gynecologic cancers, contributing to regulatory approval for unresectable or metastatic HER2 immunohistochemistry (IHC) 3+ solid tumors. Evidence in gynecologic malignancies with low HER2 expression remains limited. We evaluated T-DXd in a predominantly HER2-low, heavily pretreated population. Methods: This retrospective, single-center cohort study included 11 patients with recurrent gynecologic malignancies who initiated therapy with T-DXd at the Medical University of Innsbruck between January 2024 and February 2026 following progression on standard-of-care treatment. The cohort comprised patients with ovarian (n = 6), endometrial (n = 2), and cervical cancer (n = 3). Treatment response, survival outcomes, and adverse events were assessed. Results: Among 11 heavily pretreated patients, seven (64%) had tumors with HER2 IHC 1+, three (27%) had HER2 IHC 2+/ISH negative, and one (9%) had HER2 IHC 3+ expression. The overall response rate was 67% (6/9; 95% CI 29.9–92.5) and disease control rate was 78% (7/9; 95% CI 40.0–97.2). Kaplan–Meier median duration of response was 4.6 months (95% CI, 1.9–7.3), with two responses ongoing at 8.7 and 20.1 months. Median progression-free and overall survival were 7.0 months (95% CI, 1.6–12.4) and 12.0 months (95% CI, 8.3–15.7), respectively. Treatment-associated adverse events occurred in 73% of patients, including interstitial lung disease in two patients. Conclusions: T-DXd showed antitumor activity in this predominantly HER2-low real-world cohort. These findings support further clinical investigation of T-DXd in patients with low HER2 expressing gynecological malignancies.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2026-11-17
DOI
https://doi.org/10.3390/cancers18223673
Primary Topic
HER2/EGFR in Cancer Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Efficacy and Safety of Trastuzumab Deruxtecan in Heavily Pretreated Predominantly Low HER2 Expressing Gynecologic Malignancies

Katharina Leitner, Christian Marth, Irina Tsibulak, Verena E. Wieser et al.
4 links
Cancers
HER2/EGFR in Cancer Research
article

Efficacy and Safety of Trastuzumab Deruxtecan in Heavily Pretreated Predominantly Low HER2 Expressing Gynecologic Malignancies

Katharina Leitner, Christian Marth, Irina Tsibulak, Verena E. Wieser, Christoph Ebner, Susanne Sprung, İbrahim Alkatout, Barin Feroz, Katharina Steger
article en

Abstract

Background/Objectives: DESTINY-PanTumor02 demonstrated clinically meaningful activity of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing solid tumors, including gynecologic cancers, contributing to regulatory approval for unresectable or metastatic HER2 immunohistochemistry (IHC) 3+ solid tumors. Evidence in gynecologic malignancies with low HER2 expression remains limited. We evaluated T-DXd in a predominantly HER2-low, heavily pretreated population. Methods: This retrospective, single-center cohort study included 11 patients with recurrent gynecologic malignancies who initiated therapy with T-DXd at the Medical University of Innsbruck between January 2024 and February 2026 following progression on standard-of-care treatment. The cohort comprised patients with ovarian (n = 6), endometrial (n = 2), and cervical cancer (n = 3). Treatment response, survival outcomes, and adverse events were assessed. Results: Among 11 heavily pretreated patients, seven (64%) had tumors with HER2 IHC 1+, three (27%) had HER2 IHC 2+/ISH negative, and one (9%) had HER2 IHC 3+ expression. The overall response rate was 67% (6/9; 95% CI 29.9–92.5) and disease control rate was 78% (7/9; 95% CI 40.0–97.2). Kaplan–Meier median duration of response was 4.6 months (95% CI, 1.9–7.3), with two responses ongoing at 8.7 and 20.1 months. Median progression-free and overall survival were 7.0 months (95% CI, 1.6–12.4) and 12.0 months (95% CI, 8.3–15.7), respectively. Treatment-associated adverse events occurred in 73% of patients, including interstitial lung disease in two patients. Conclusions: T-DXd showed antitumor activity in this predominantly HER2-low real-world cohort. These findings support further clinical investigation of T-DXd in patients with low HER2 expressing gynecological malignancies.

CancersVol. 18(22)
Innsbruck Medical University (AT), Tirol Kliniken (AT)
Good health and well-being
HER2/EGFR in Cancer Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon